

Stavros Gravas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1343696/publications.pdf>

Version: 2024-02-01

83
papers

3,475
citations

411340

20
h-index

162838

57
g-index

86
all docs

86
docs citations

86
times ranked

3747
citing authors

#	ARTICLE	IF	CITATIONS
1	The use of an artificial neural network in the evaluation of the extracorporeal shockwave lithotripsy as a treatment of choice for urinary lithiasis. <i>Asian Journal of Urology</i> , 2022, 9, 132-138.	0.5	3
2	Conventional white light imaging-assisted transurethral resection of bladder tumour (TURBT) versus IMAGE1S-assisted TURBT in non-muscle-invasive bladder cancer patients: trial protocol and 18-months results. <i>World Journal of Urology</i> , 2022, 40, 727-738.	1.2	4
3	Outcomes of combination therapy with daily tadalafil 5 mg plus tamsulosin 0.4 mg to treat lower urinary tract symptoms and erectile dysfunction in men with or without metabolic syndrome. <i>Minerva Urology and Nephrology</i> , 2022, 73, .	1.3	3
4	Hot Topics in the Clinical Practice Guidelines for Treatment of Male Lower Urinary Tract Symptoms due to Benign Prostatic Obstruction. <i>European Urology Focus</i> , 2022, 8, 396-398.	1.6	6
5	European Association of Urology Guidelines on Male Urinary Incontinence. <i>European Urology</i> , 2022, 82, 387-398.	0.9	37
6	TURPxit or not: the guidelines perspectiveâ€”Panta Rhei. <i>World Journal of Urology</i> , 2021, 39, 2399-2400.	1.2	1
7	Impact of COVID-19 on medical education: introducing homo digitalis. <i>World Journal of Urology</i> , 2021, 39, 1997-2003.	1.2	22
8	Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial. <i>European Urology Focus</i> , 2021, 7, 432-439.	1.6	5
9	Preservation of antegrade ejaculation after surgical relief of benign prostatic obstruction is a valid endpoint. <i>World Journal of Urology</i> , 2021, 39, 2277-2289.	1.2	3
10	Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. <i>European Urology</i> , 2021, 79, 492-504.	0.9	20
11	Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luoâ€™s Letter to the Editor re: Cosimo De Nunzio, Benjamin Brucker, Thomas Bschiepfer, et al. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. <i>Eur Urol</i> 2021;79:492â€”504. <i>European Urology</i> , 2021, 79, e147-e148.	0.9	1
12	A Systematic Review of Patientsâ€™ Values, Preferences, and Expectations for the Diagnosis and Treatment of Male Lower Urinary Tract Symptoms. <i>European Urology</i> , 2021, 79, 796-809.	0.9	65
13	Endothelin-1 indicates unfavorable prognosis in primary high-grade non-muscle-invasive urothelial bladder cancer. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 143-147.	0.4	2
14	Translation and validation of the Italian version of the user version of the Mobile Application Rating Scale (uMARS). <i>Journal of Preventive Medicine and Hygiene</i> , 2021, 62, E243-E248.	0.9	0
15	Mind the gap: management of benign prostatic obstruction (BPO) surgical candidates on antithrombotics. <i>World Journal of Urology</i> , 2020, 38, 247-248.	1.2	0
16	Crossâ€”continental comparison of safety and protection measures amongst urologists during COVIDâ€”19. <i>International Journal of Urology</i> , 2020, 27, 981-989.	0.5	3
17	Lasers in Transurethral Enucleation of the Prostateâ€”Do We Really Need Them. <i>Journal of Clinical Medicine</i> , 2020, 9, 1412.	1.0	23
18	European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. <i>European Urology</i> , 2020, 78, 21-28.	0.9	239

#	ARTICLE	IF	CITATIONS
19	Impact of COVID-19 on Urology Practice: A Global Perspective and Snapshot Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1730.	1.0	16
20	Prioritising Urological Surgery in the COVID-19 Era: A Global Reflection on Guidelines. <i>European Urology Focus</i> , 2020, 6, 1104-1110.	1.6	20
21	The Clinical Impact of Hexanic Extract of <i>Serenoa repens</i> in Men with Prostatic Inflammation: A Post Hoc Analysis of a Randomized Biopsy Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 957.	1.0	2
22	Mobile Health in Urology: The Good, the Bad and the Ugly. <i>Journal of Clinical Medicine</i> , 2020, 9, 1016.	1.0	10
23	Outcomes of combination therapy with daily Tadalafil 5mg plus Tamsulosin 0.4mg to treat lower urinary tract symptoms and erectile dysfunction in men with or without metabolic syndrome. <i>Minerva Urology and Nephrology</i> , 2020, , .	1.3	1
24	The effect of hexanic extract of <i>Serenoa repens</i> on prostatic inflammation: results from a randomized biopsy study. <i>World Journal of Urology</i> , 2019, 37, 539-544.	1.2	28
25	Desensitization of cAMP Accumulation via Human β 3-Adrenoceptors Expressed in Human Embryonic Kidney Cells by Full, Partial, and Biased Agonists. <i>Frontiers in Pharmacology</i> , 2019, 10, 596.	1.6	7
26	Tadalafil 5 mg Alone or in Combination with Tamsulosin 0.4 mg for the Management of Men with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Prospective Observational Trial. <i>Journal of Clinical Medicine</i> , 2019, 8, 1126.	1.0	12
27	What Is the Required Certainty of Evidence for the Implementation of Novel Techniques for the Treatment of Benign Prostatic Obstruction?. <i>European Urology Focus</i> , 2019, 5, 351-356.	1.6	34
28	Current and emerging mechanical minimally invasive therapies for benign prostatic obstruction. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721982897.	0.9	15
29	Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2019, 75, 788-798.	0.9	46
30	Primary High-Grade Non-Muscle-Invasive Bladder Cancer: High NF κ B Expression in Tumor Specimens Distinguishes Patients Who are at Risk for Disease Progression. <i>Pathology and Oncology Research</i> , 2019, 25, 225-231.	0.9	7
31	Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base. <i>Therapeutic Advances in Urology</i> , 2018, 10, 79-92.	0.9	31
32	Lower Urinary Tract Symptoms Including Bladder Outlet Obstruction: What's New in Diagnostics?. <i>European Urology Focus</i> , 2018, 4, 14-16.	1.6	8
33	Reply to Jae Hung Jung, Julia L. Han, and Philipp Dahm's Letter to the Editor re: Vasileios I. Sakalis, Markos Karavitakis, Dina Bedretdinova, et al. Medical Treatment of Nocturia in Men with Lower Urinary Tract Symptoms: Systematic Review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms. <i>Eur Urol</i> 2017;72:757-69. <i>European Urology</i> , 2018, 73, e60-e62.	0.9	0
34	Practice Patterns in Diagnosis and Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia among General Practitioners: Lessons Learnt from a Greek Survey. <i>Balkan Medical Journal</i> , 2018, 35, 287-288.	0.3	0
35	The Relationship Between Inflammation and LUTS/BPH. , 2018, , 31-50.		2
36	Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICIERS 2015). <i>Neurourology and Urodynamics</i> , 2017, 36, 882-893.	0.8	44

#	ARTICLE	IF	CITATIONS
37	Do β_3 -adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release?. American Journal of Physiology - Renal Physiology, 2017, 313, F859-F861.	1.3	9
38	Medical Treatment of Nocturia in Men with Lower Urinary Tract Symptoms: Systematic Review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms. European Urology, 2017, 72, 757-769.	0.9	59
39	Systematic Review of the Performance of Noninvasive Tests in Diagnosing Bladder Outlet Obstruction in Men with Lower Urinary Tract Symptoms. European Urology, 2017, 71, 391-402.	0.9	64
40	New therapeutic strategies for the treatment of male lower urinary tract symptoms. Research and Reports in Urology, 2016, 8, 51.	0.6	8
41	Generalized Lymphadenopathy of Prostate Adenocarcinoma Origin. A Case Series. Urology, 2016, 91, e3-e4.	0.5	0
42	Male Lower Urinary Tract Symptoms and Cardiovascular Events: A Systematic Review and Meta-analysis. European Urology, 2016, 70, 788-796.	0.9	84
43	The Impact of Central Obesity on Storage Luts and Urinary Incontinence After Prostatic Surgery. Current Urology Reports, 2016, 17, 61.	1.0	18
44	Safety and tolerability of β_3 -adrenoceptor agonists in the treatment of overactive bladder syndrome – insight from transcriptome and experimental studies. Expert Opinion on Drug Safety, 2016, 15, 647-657.	1.0	42
45	A single dose of meropenem is superior to ciprofloxacin in preventing infections after transrectal ultrasound-guided prostate biopsies in the era of quinolone resistance. World Journal of Urology, 2016, 34, 1555-1559.	1.2	12
46	Prostate Volume as a Risk Factor for Lower Urinary Tract Symptoms: The Quest Continues. European Urology, 2016, 69, 892-893.	0.9	2
47	Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia. Therapeutic Advances in Urology, 2016, 8, 19-28.	0.9	12
48	Feasibility and safety of radical cystectomy under combined spinal and epidural anesthesia in octogenarian patients with ASA score ≥ 3 : A case series. Canadian Urological Association Journal, 2015, 9, 500.	0.3	5
49	Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia. Drug Design, Development and Therapy, 2015, 9, 1707.	2.0	10
50	EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. European Urology, 2015, 67, 1099-1109.	0.9	735
51	Re: Drug Adherence and Clinical Outcomes for Patients Under Pharmacological Therapy for Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Population-based Cohort Study. European Urology, 2015, 68, 338-339.	0.9	0
52	Tolterodine in the Treatment of Male LUTS. Current Urology Reports, 2015, 16, 60.	1.0	9
53	Endothelin-1 overexpression: a potential biomarker of unfavorable prognosis in non-metastatic muscle-invasive bladder cancer. Tumor Biology, 2015, 36, 4699-4705.	0.8	4
54	Sodium hyaluronate and chondroitin sulfate replenishment therapy can improve nocturia in men with post-radiation cystitis: results of a prospective pilot study. BMC Urology, 2015, 15, 65.	0.6	20

#	ARTICLE	IF	CITATIONS
55	Tolterodine extended release in the treatment of male oab/storage luts: a systematic review. BMC Urology, 2014, 14, 84.	0.6	13
56	Quality of Life and Sexual Health in the Aging of PCa Survivors. International Journal of Endocrinology, 2014, 2014, 1-16.	0.6	13
57	Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG. Tumor Biology, 2014, 35, 4185-4189.	0.8	17
58	EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. European Urology, 2013, 64, 118-140.	0.9	990
59	Focal therapy for prostate cancer: patient selection and evaluation. Expert Review of Anticancer Therapy, 2012, 12, 77-86.	1.1	4
60	Laser Treatment of Benign Prostatic Obstruction: Basics and Physical Differences. European Urology, 2012, 61, 317-325.	0.9	123
61	Is there a learning curve for photodynamic diagnosis of bladder cancer with hexaminolevulinate hydrochloride?. Canadian Journal of Urology, 2012, 19, 6269-73.	0.0	14
62	Critical review of lasers in benign prostatic hyperplasia (BPH). BJU International, 2011, 107, 1030-1043.	1.3	137
63	Extracorporeal shock-wave lithotripsy and garlic consumption: a lesson to learn. Urological Research, 2010, 38, 61-63.	1.5	8
64	Current status of 5 α -reductase inhibitors in the management of lower urinary tract symptoms and BPH. World Journal of Urology, 2010, 28, 9-15.	1.2	77
65	Relevance of benign prostatic hyperplasia and associated conditions for urologists, health care systems, and society. World Journal of Urology, 2010, 28, 1-2.	1.2	4
66	Is Focal Therapy an Alternative to Active Surveillance?. Journal of Endourology, 2010, 24, 855-860.	1.1	4
67	Editorial Comment on: Chronic Pelvic Pain and Lower Urinary Tract Symptoms in Both Sexes: Analysis of 2749 Participants of an Urban Health Screening Project. European Urology, 2009, 55, 508.	0.9	0
68	Comment on: Management of forgotten ureteral stents with holmium laser. Lasers in Medical Science, 2009, 24, 293-294.	1.0	2
69	Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia. European Urology Supplements, 2009, 8, 513-522.	0.1	9
70	Advances in Ultrasound Technology in Oncologic Urology. Urologic Clinics of North America, 2009, 36, 133-145.	0.8	15
71	Male lower urinary tract symptoms: how do symptoms guide our choice of treatment?. Current Opinion in Urology, 2009, 19, 49-54.	0.9	15
72	Endobronchial metastasis from prostate cancer. International Urology and Nephrology, 2008, 40, 961-964.	0.6	10

#	ARTICLE	IF	CITATIONS
73	Editorial Comment on: Update on Training Models in Endourology: A Qualitative Systematic Review of the Literature between January 1980 and April 2008. <i>European Urology</i> , 2008, 54, 1260-1261.	0.9	0
74	Minimally Invasive Treatment of Male Lower Urinary Tract Symptoms. <i>Urologic Clinics of North America</i> , 2008, 35, 505-518.	0.8	7
75	Translation of benign prostatic hyperplasia guidelines into clinical practice. <i>Current Opinion in Urology</i> , 2008, 18, 56-60.	0.9	9
76	Juvenile Granulosa Cell Tumor of the Epididymis. <i>Urologia Internationalis</i> , 2007, 78, 278-279.	0.6	3
77	Transurethral microwave thermotherapy: from evidence-based medicine to clinical practice. <i>Current Opinion in Urology</i> , 2007, 17, 12-16.	0.9	3
78	Durability of 30-Minute High-Energy Transurethral Microwave Therapy for Treatment of Benign Prostatic Hyperplasia: A Study of 213 Patients With and Without Urinary Retention. <i>Urology</i> , 2007, 69, 854-858.	0.5	19
79	Feasibility of Percutaneous Nephrolithotomy under Assisted Local Anaesthesia: A Prospective Study on Selected Patients with Upper Urinary Tract Obstruction. <i>European Urology</i> , 2007, 51, 224-228.	0.9	65
80	Epidemiologic trends indicate the prevalence of obesity will rise globally. <i>European Urology</i> , 2007, 52, 204-5.	0.9	2
81	Forgotten, Encrusted Ureteral Stents: A Challenging Problem with an Endourologic Solution. <i>Journal of Endourology</i> , 2006, 20, 1045-1049.	1.1	41
82	SEEKING EVIDENCE THAT CELL KILL GUIDED THERMOTHERAPY GIVES RESULTS NOT INFERIOR TO THOSE OF TRANSURETHRAL PROSTATE RESECTION: RESULTS OF A POOLED ANALYSIS OF 3 STUDIES OF FEEDBACK TRANSURETHRAL MICROWAVE THERMOTHERAPY. <i>Journal of Urology</i> , 2005, 174, 1002-1006.	0.2	13
83	Transurethral Microwave Thermotherapy: The Gold Standard for Minimally Invasive Therapies for Patients with Benign Prostatic Hyperplasia?. <i>Journal of Endourology</i> , 2003, 17, 245-251.	1.1	44